Clinical trialNo phase (not a drug trial)Unknown
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- No phase (not a drug trial)
- Status
- Unknown
- Study type
- Interventional
- Start
- 1 February 2023
- Listed end
- 1 February 2025
- Enrollment
- 100 participants
- Sites
- 1
- Primary outcomes
- Progression-free survival
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 12 April 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in advanced or metastatic pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before first-line chemotherapy initiation and at the first imaging assessment after chemotherapy.